

***In Vitro* Models of Human Toxicity Pathways**

Chairpersons: David Dix, U.S. EPA, RTP, NC
Rusty Thomas, The Hamner Institutes for Health
Sciences, RTP, NC

Sponsor: *In Vitro* and Alternative Methods Specialty Section


Endorsed by: Risk Assessment Specialty Section
Regulatory and Safety Evaluation Specialty Section

Human experience
1–3 studies/year

Standard rodent toxicological tests
10–100/year

Alternative animal models
100–10,000/year

Biochemical- and cell-based *in vitro* assays
≥10,000/day



High-throughput molecular mechanisms


Immediate human relevance



ToxCast Data Analysis Summit

EPA RTP campus, May 14-15, 2009

- Hosted by EPA's National Center for Computational Toxicology
- Modeling of ToxCast data to generate predictive signatures
- Derivation of significant toxicity pathways
- Committed to stakeholder involvement and public release of data and results
- ToxCast summit website-
<http://www.epa.gov/ncct/toxcast/summit.html>



In Vitro Models of Human Toxicity Pathways

Evaluation of the ToxCast Suite of Cellular and Molecular Assays for Prediction of *In Vivo* Toxicity

Keith Houck, U.S. EPA, Research Triangle Park, NC

Use of Nuclear Reporter Assays to Investigate Species Differences in Toxicity

Richard Pepper, Syngenta Crop Protection Inc., Greensboro, NC

Towards New *In Vitro* Toxicology Strategies for Decision Making: Acute Toxicity as a Case Study

Gladys Ouedraogo, L'Oreal, Aulnay sous bois, France

Three-Dimensional Human Cellular and Metabolizing Enzyme Microarrays for High-Throughput Toxicity Screening

Jonathan Dordick, Rensselaer Polytechnic Institute, Troy, NY

Microscale Liver Models for Drug Development and Toxicity Screening

Sangeeta Bhatia, MIT, Cambridge, MA